A 346-publication analysis finds rapidly expanding research on SGLT2 inhibitors across cancer safety, antitumor mechanisms, ...

(9926.HK) ("Akeso" or the "Company") announced that at the 2025 ESMO Asia Congress, updated results from the pivotal Phase ...

A 2026 review proposes that SFRP4 may inhibit tumor angiogenesis through integrin-linked disruption of Wnt–β-catenin ...

Lunit partners with US Summit to use AI biomarkers for ivonescimab response Ai-powered tissue analysis to pinpoint responders ...

Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, ...

Arcus Biosciences casdatifan combinations showed superior or competitive PFS and response rates versus historical benchmarks.

OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative ...

PD-1 bispecific antibodies combine checkpoint blockade with CTLA-4 or VEGF targeting. Can one engineered molecule offer ...

Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of ...

CROWN ctDNA data link early lorlatinib progression to genomic complexity, TP53 and bypass pathways rather than new ALK ...